MaxCyte, a cell-engineering company, celebrates its 25th anniversary, focusing on providing enabling technologies for cell therapeutics development. The company offers Flow Electroporation technology, part of their proprietary ExPERT platform, to support biomedical innovations in human health. MaxCyte has signed 29 Strategic Platform License agreements with cell therapy developers, including the development of the FDA-approved CASGEVY® non-viral cell therapy. They recently moved to a larger facility in Maryland to expand their manufacturing and research capabilities. MaxCyte aims to continue supporting customers in advancing cell and gene therapy, leveraging their technology and experience to improve patients’ lives in the evolving bio-based medicine field.
Source link
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics
